Stay updated on Safety and Tolerability of Nivolumab and Cabiralizumab Clinical Trial
Sign up to get notified when there's something new on the Safety and Tolerability of Nivolumab and Cabiralizumab Clinical Trial page.

Latest updates to the Safety and Tolerability of Nivolumab and Cabiralizumab Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedOnly minor UI/version changes are observed: a new 'Revision: v3.4.2' label and removal of the older funding/operating status notice. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check21 days agoChange DetectedAdded a government funding lapse notice with status updates and links to cc.nih.gov and opm.gov; added release note Revision: v3.4.1; removed the prior release note Revision: v3.4.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check28 days agoChange DetectedAdded 'Show glossary' and updated footer/status labels to 'Last Update Submitted that Met QC Criteria' and 'No FEAR Act Data', alongside a revision note 'Revision: v3.4.0'. Removed 'Last Update Submitted that met QC Criteria', 'No FEAR Act data', and prior 'Revision: v3.3.4'.SummaryDifference0.2%

- Check42 days agoChange DetectedRevision: v3.3.4 added and v3.3.3 removed; changes are limited to revision metadata and do not affect study details or user actions. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check64 days agoChange DetectedFooter shows Revision: v3.3.3 and removal of the HHS Vulnerability Disclosure and Revision: v3.3.2 notices. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check85 days agoChange DetectedThe page shows a revision update from v3.3.1 to v3.3.2. No study content, eligibility criteria, outcomes, or other critical information was changed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Safety and Tolerability of Nivolumab and Cabiralizumab Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety and Tolerability of Nivolumab and Cabiralizumab Clinical Trial page.